R. C. French

Pfizer (United States)

Papers

1

Total Citations

12

H-Index

1

About

Dr. R. C. French is a clinical microbiologist whose research centers on the detection and neutralization of bacterial toxins, with a particular focus on *Clostridioides difficile* infections. Their most significant contribution is the development and clinical validation of an automated cell cytotoxicity neutralization assay (CCNA) for detecting *C. difficile* toxins in stool samples, a breakthrough that addresses the critical need for rapid, accurate, and high-throughput diagnostics in clinical settings. This work, published in 2021, has already garnered 12 citations, underscoring its immediate impact on improving patient care by reducing turnaround times and standardizing toxin detection. Dr. French’s expertise bridges automation, immunology, and infectious disease diagnostics, offering a practical solution to a long-standing challenge in hospital laboratories. Their research not only enhances the reliability of *C. difficile* diagnosis but also sets a precedent for integrating automated systems into routine clinical workflows, paving the way for more efficient management of healthcare-associated infections.

Research Focus

Key Achievements

1
H-Index
1
Papers
12
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Development and clinical validation of an automated cell cytotoxicity neutralization assay for detecting Clostridioides difficile toxins in clinically relevant stools samples
12 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Pfizer (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago